185 related articles for article (PubMed ID: 31164431)
1. Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis.
Glassberg MK; Wijsenbeek MS; Gilberg F; Petzinger U; Kirchgaessler KU; Albera C
Eur Respir J; 2019 Sep; 54(3):. PubMed ID: 31164431
[TBL] [Abstract][Full Text] [Related]
2. Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
Nathan SD; Costabel U; Albera C; Behr J; Wuyts WA; Kirchgaessler KU; Stauffer JL; Morgenthien E; Chou W; Limb SL; Noble PW
Respir Med; 2019 Jul; 153():44-51. PubMed ID: 31153107
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function.
Albera C; Costabel U; Fagan EA; Glassberg MK; Gorina E; Lancaster L; Lederer DJ; Nathan SD; Spirig D; Swigris JJ
Eur Respir J; 2016 Sep; 48(3):843-51. PubMed ID: 27471208
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis: Extended analysis of phase III trial in Japan.
Taguchi Y; Ebina M; Hashimoto S; Ogura T; Azuma A; Taniguchi H; Kondoh Y; Suga M; Takahashi H; Nakata K; Sugiyama Y; Kudoh S; Nukiwa T;
Respir Investig; 2015 Nov; 53(6):279-87. PubMed ID: 26521105
[TBL] [Abstract][Full Text] [Related]
5. Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis.
Ley B; Swigris J; Day BM; Stauffer JL; Raimundo K; Chou W; Collard HR
Am J Respir Crit Care Med; 2017 Sep; 196(6):756-761. PubMed ID: 28471697
[TBL] [Abstract][Full Text] [Related]
6. Pirfenidone: in idiopathic pulmonary fibrosis.
Carter NJ
Drugs; 2011 Sep; 71(13):1721-32. PubMed ID: 21902295
[TBL] [Abstract][Full Text] [Related]
7. Marked Improvement with Pirfenidone in a Patient with Idiopathic Pulmonary Fibrosis.
Miyamoto A; Morokawa N; Takahashi Y; Ogawa K; Takeyasu M; Murase K; Hanada S; Uruga H; Mochizuki S; Takaya H; Kurosaki A; Kishi K
Intern Med; 2016; 55(6):657-61. PubMed ID: 26984086
[TBL] [Abstract][Full Text] [Related]
8. Intraindividual response to treatment with pirfenidone in idiopathic pulmonary fibrosis.
Loeh B; Drakopanagiotakis F; Bandelli GP; von der Beck D; Tello S; Cordani E; Rizza E; Barrocu L; Markart P; Seeger W; Guenther A; Albera C
Am J Respir Crit Care Med; 2015 Jan; 191(1):110-3. PubMed ID: 25551350
[No Abstract] [Full Text] [Related]
9. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
Poletti V; Ravaglia C; Tomassetti S
Expert Rev Respir Med; 2014 Oct; 8(5):539-45. PubMed ID: 25113033
[TBL] [Abstract][Full Text] [Related]
10. Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis.
Arai T; Inoue Y; Sasaki Y; Tachibana K; Nakao K; Sugimoto C; Okuma T; Akira M; Kitaichi M; Hayashi S
Respir Investig; 2014 Mar; 52(2):136-43. PubMed ID: 24636270
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis: A real-world observational study.
Tzouvelekis A; Ntolios P; Karampitsakos T; Tzilas V; Anevlavis S; Bouros E; Steiropoulos P; Koulouris N; Stratakos G; Froudarakis M; Bouros D
Pulm Pharmacol Ther; 2017 Oct; 46():48-53. PubMed ID: 28843616
[TBL] [Abstract][Full Text] [Related]
12. Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation.
Maher TM; Lancaster LH; Jouneau S; Morrison L; Lederer DJ; Molina-Molina M; Bendstrup E; Kirchgaessler KU; Gilberg F; Axmann J; Petzinger U; Noble PW
Ann Am Thorac Soc; 2019 Jul; 16(7):927-930. PubMed ID: 30950636
[No Abstract] [Full Text] [Related]
13. Pirfenidone treatment of idiopathic pulmonary fibrosis.
Azuma A
Ther Adv Respir Dis; 2012 Apr; 6(2):107-14. PubMed ID: 22333982
[TBL] [Abstract][Full Text] [Related]
14. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
Noble PW; Albera C; Bradford WZ; Costabel U; Glassberg MK; Kardatzke D; King TE; Lancaster L; Sahn SA; Szwarcberg J; Valeyre D; du Bois RM;
Lancet; 2011 May; 377(9779):1760-9. PubMed ID: 21571362
[TBL] [Abstract][Full Text] [Related]
15. [Idiopathic pulmonary fibrosis: treatment with pirfenidone].
Cano-Jiménez E
Arch Bronconeumol; 2012 Oct; 48 Suppl 2():16-8. PubMed ID: 23630972
[No Abstract] [Full Text] [Related]
16. Pirfenidone for idiopathic pulmonary fibrosis.
Bouros D
Lancet; 2011 May; 377(9779):1727-9. PubMed ID: 21571363
[No Abstract] [Full Text] [Related]
17. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.
Nathan SD; Albera C; Bradford WZ; Costabel U; Glaspole I; Glassberg MK; Kardatzke DR; Daigl M; Kirchgaessler KU; Lancaster LH; Lederer DJ; Pereira CA; Swigris JJ; Valeyre D; Noble PW
Lancet Respir Med; 2017 Jan; 5(1):33-41. PubMed ID: 27876247
[TBL] [Abstract][Full Text] [Related]
18. Assessing the Therapeutic Response to Pirfenidone in Idiopathic Pulmonary Fibrosis: Can We Do Better than with Forced Vital Capacity Alone?
Hosein K; Le J; Mura M
Lung; 2017 Feb; 195(1):101-105. PubMed ID: 27858160
[TBL] [Abstract][Full Text] [Related]
19. A 2-Year Observational Study in Patients Suffering from Idiopathic Pulmonary Fibrosis and Treated with Pirfenidone: A French Ancillary Study of PASSPORT.
Jouneau S; Gamez AS; Traclet J; Nunes H; Marchand-Adam S; Kessler R; Israël-Biet D; Borie R; Strombom I; Scalori A; Crestani B; Valeyre D; Cottin V
Respiration; 2019; 98(1):19-28. PubMed ID: 30965332
[TBL] [Abstract][Full Text] [Related]
20. Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib.
Karimi-Shah BA; Chowdhury BA
N Engl J Med; 2015 Mar; 372(13):1189-91. PubMed ID: 25806913
[No Abstract] [Full Text] [Related]
[Next] [New Search]
